Title : Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).

Pub. Date : 2014 May

PMID : 25876473






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: Compared with interferon beta-1a intramuscular, fingolimod 0.5mg significantly reduced annualized relapse rate in patients who were treatment naive, received prior interferon-beta treatment, discontinued prior disease-modifying therapy for unsatisfactory therapeutic effect, or had prior disease-modifying therapy duration of >=1 year (P<=0.05, all comparisons). Fingolimod Hydrochloride interferon beta 1 Homo sapiens
2 Significant reductions were also seen with fingolimod 1.25mg for treatment-naive and prior interferon-beta-treated patients. Fingolimod Hydrochloride interferon beta 1 Homo sapiens